Oppenheimer Maintains Outperform on Innoviva, Lowers Price Target to $34
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Les Sulewski maintains Innoviva (NASDAQ:INVA) with a Outperform and lowers the price target from $35 to $34.
Oppenheimer analyst Les Sulewski maintains Innoviva (NASDAQ:INVA) with a Outperform and lowers the price target from $35 to $34.